News

New investors include Cormorant Asset Management, Deerfield Management, Fidelity Management and Research Company, Hillhouse Capital, NS Investment, OrbiMed, Sirona Capital, and Venrock Healthcare Partners. Current investors, including The

Duvelisib is a first-in-class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, for which Verastem is seeking full approval for the treatment of relapsed or refractory chronic

IONIS-AZ6-2.5-LRx has been designed by the US company to inhibit an undisclosed target for the treatment of patients having nonalcoholic steatohepatitis (NASH). AstraZeneca and Ionis had previously entered

The trail demonstrated that upadacitinib achieved the primary endpoints of ACR20a and clinical remission remissionb against placebo placebo, as well as achieved all ranked secondary endpoints against either

EpiDestiny is eligible to receive more than 400 million US dollars in upfront, development and sales milestone payments and will get royalties on net sales. EpiDestiny and Novo

The approval is for patients who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line

As per the deal that has been approved unanimously by the boards of the two companies, Novartis will pay $218 for each share of AveXis. The deal will

The external data monitoring committee (eDMC) concluded that the pivotal phase 3 Echo-301/Keynote-205 study has failed to achieve the primary endpoint of improving progression-free survival in the overall

These lawsuits allege that the aforementioned companies infringe the '305 patent, which was issued on April 3rd and has been submitted for listing in the FDA's Orange Book.